TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 112 resultados LastUpdate Última actualización 20/05/2019 [16:49:00] pdf PDF

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days

Página1 de 5 nextPage   por página


REPORTING OF GLYCEMIC VARIABILITY FROM CONTINUOUS GLUCOSE MONITORING

NºPublicación: US2019142314A1 16/05/2019

Solicitante:

SENSEONICS INCORPORATED [US]

Resumen de: US2019142314A1

In one aspect, a method of estimating an HbA1c level is provided. The method may include obtaining a first and second glucose measurement, adding the first and the second glucose measurements to a glucose measurement data set, and calculating an estimated HbA1c level using at least the glucose measurement data set. In another aspect, a method of calculating a range of an estimated HbA1c level is provided. The method may comprise at least calculating an estimated HbA1c level and a standard deviation of the estimated HbA1c level using a glucose measurement data set, and combining the estimated HbA1c level with the standard deviation of the estimated HbA1c level to acquire the range of the estimated HbA1c level. In another aspect, a glucose monitoring device may display glycemic variability of an individual.

traducir

IMPLANTABLE GLUCOSE SENSORS HAVING A BIOSTABLE SURFACE

NºPublicación: US2019142317A1 16/05/2019

Solicitante:

INTERFACE BIOLOGICS INC [CA]

WO_2017195035_A1

Resumen de: US2019142317A1

Disclosed are implantable glucose sensors having a biostable surface. The implantable glucose sensor includes a glucose detector and an enclosure defining a boundary between an internal space and an external space. The enclosure includes a semipermeable biointerface film containing a base polymer and a biostabilizing additive. The semipermeable biointerface film has a biostable surface and is permeable to glucose. The working electrode is disposed inside the internal space, and the biostable surface faces the external space or faces both the internal and the external spaces. Also disclosed are methods of preparation of the semipermeable biointerface films adapted for use in the implantable glucose sensors. Further, disclosed are methods of monitoring glucose levels in a subject through the use of an implantable glucose sensor. The implantable glucose sensor may be an implantable electrochemical glucose sensor, in which the glucose detector is a working electrode. Alternatively, the implantable glucose sensor may be an implantable optical glucose sensor, in which the glucose detector is a glucose recognition element including a glucose-binding fluorophore.

traducir

WEARABLE INSULIN PUMP IN A COMPACT AND REUSABLE FORM FACTOR

NºPublicación: US2019143031A1 16/05/2019

Solicitante:

ADMANI RICHARD F [US]

Resumen de: US2019143031A1

A wearable, adherable, tubeless, stand-alone, two-part system insulin pump includes a patch component in a first housing, wherein the patch component includes an adhesive pad, a fixed needle, a flexible tube, and collapsible reservoir connected to the flexible tube and storing insulin; and a pump component in a second housing, wherein the pump component includes a peristaltic pump configured that includes a rotor and more than one roller to pump the insulin from the flexible tube to the fixed needle and a controller for control thereof; wherein the first housing and the second housing are selectively connected to one another, and wherein the pump component is reusable with one or more pump components. Of note, the pump can support other drugs besides insulin.

traducir

TIERED TIME-IN-RANGE GUIDING INTERFACES FOR DIABETES MANAGEMENT

NºPublicación: US2019147139A1 16/05/2019

Solicitante:

VERILY LIFE SCIENCES LLC [US]

Resumen de: US2019147139A1

Introduced here are diabetes management platforms able to guide people with diabetes toward a glycemic target. Rather than state the absolute amount of glucose within the blood, the diabetes management platform can instead produce personalized glycemic goals based on the physiological data associated with an individual. For example, if the diabetes management platform determines that the time spent within a first glycemic range exceeds a specified threshold, then the diabetes management platform may recommend that the individual attempt to keep their blood glucose level within a second glycemic range. Generally, the second glycemic range is closer than the first glycemic range to a target glycemic range corresponding to a healthy glycemic state.

traducir

METHOD FOR ADJUSTING A BOLUS AMOUNT OF INSULIN, DEVICE AND MEDICAL SYSTEM

NºPublicación: WO2019091998A1 16/05/2019

Solicitante:

ROCHE DIABETES CARE GMBH [DE]
ROCHE DIABETES CARE INC [US]
HOFFMANN LA ROCHE [CH]

EP_3483891_A1

Resumen de: WO2019091998A1

The present disclosure refers to a method for adjusting a bolus amount of insulin for a meal event using a control unit having a processing unit and a touch screen display as well as a medical control device and a medical system configured to perform the method. Additionally the present disclosure refers to a computer program or computer program product which when executed performs the method.

traducir

BASAL TITRATION WITH ADAPTIVE TARGET GLUCOSE LEVEL

NºPublicación: US2019147999A1 16/05/2019

Solicitante:

NOVO NORDISK AS [DK]

CN_109661196_A

Resumen de: US2019147999A1

Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject and insulin injection data is obtained. A first glycaemic risk measures is determined, where the first risk glycaemic risk measure is i) glucose level variability across the glucose measurements, (ii) a variability in fasting glucose levels calculated from the glucose measurements, (iii) a minimum observed glucose measurement in the plurality of glucose measurements (iv) rate of change in ISF, or (v) adherence values. A fasting blood glucose target function is computed based upon at least the first glycaemic risk measure thereby obtaining an updated target fasting blood glucose level that is between a minimum and maximum target fasting blood glucose level. The long acting insulin medicament dosage is adjusted based upon the updated target fasting blood glucose level.

traducir

SYSTEM AND METHOD FOR NON-INVASIVE CONTINUOUS REAL-TIME BLOOD GLUCOSE MONITORING

NºPublicación: WO2019094820A1 16/05/2019

Solicitante:

GLUCO Z GMBH [CH]
ISMAIL NAJIB KHALED ABOU [US]

US_2019142313_A1

Resumen de: WO2019094820A1

A wearable blood glucose monitoring device, apparatus, and method of measuring a blood glucose level are provided. The method includes an oscillator assembly that transmits microwaves at an oscillator frequency based on an input impedance. The input impedance is associated with the permittivity of blood in a user's blood vessel. The method also includes a frequency detection circuit that detects a first oscillator frequency at a first time and a second oscillator frequency at a second time. The method further includes a main control board that receives an indication of a user's condition, compares the first oscillator frequency with the second oscillator frequency to determine a frequency drift, calibrates the frequency drift based on the received indication of the condition of the user, and determines a blood glucose level of the user based on the calibrated frequency drift. A corresponding wearable blood glucose monitoring device and apparatus are also provided.

traducir

HANDHELD PROCESSING DEVICE INCLUDING MEDICAL APPLICATIONS FOR MINIMALLY AND NON INVASIVE GLUCOSE MEASUREMENTS

NºPublicación: US2019142283A1 16/05/2019

Solicitante:

CERCACOR LABORATORIES INC [US]

US_2015245773_A1

Resumen de: US2019142283A1

The present disclosure includes a handheld processing device including medical applications for minimally and noninvasive glucose measurements. In an embodiment, the device creates a patient specific calibration using a measurement protocol of minimally invasive measurements and noninvasive measurements, eventually creating a patient specific noninvasive glucometer. Additionally, embodiments of the present disclosure provide for the processing device to execute medical applications and non-medical applications.

traducir

NON-INVASIVE BLOOD SUGAR MEASUREMENT METHOD AND DEVICE USING OPTICAL REFLECTOMETRY

NºPublicación: US2019142312A1 16/05/2019

Solicitante:

DADAM MICRO INC [KR]

WO_2017188675_A1

Resumen de: US2019142312A1

A non-invasive blood sugar measurement device using optical reflectometry is provided. According to an embodiment of the present invention, provided are a specific configuration and method, the configuration comprising: a light generation means for generating light to be emitted at the skin to be measured when OTDR and OFDR are used; an optical measurement means for measuring the intensity of light; an optical system for emitting the generated light at the skin to be measured and transmitting reflected light to the optical measurement means; an analysis means for analyzing collected reflected light on the basis of a change in the intensity of the reflective light with respect to time by using optical reflectometry; and a blood sugar calculation means for calculating, on the basis of the analysis result, a blood sugar level of the skin to be measured.

traducir

SYSTEM AND METHOD FOR NON-INVASIVE CONTINUOUS REAL-TIME BLOOD GLUCOSE MONITORING

NºPublicación: US2019142313A1 16/05/2019

Solicitante:

GLUCO Z GMBH [CH]

Resumen de: US2019142313A1

A wearable blood glucose monitoring device, apparatus, and method of measuring a blood glucose level are provided. The method includes an oscillator assembly that transmits microwaves at an oscillator frequency based on an input impedance. The input impedance is associated with the permittivity of blood in a user's blood vessel. The method also includes a frequency detection circuit that detects a first oscillator frequency at a first time and a second oscillator frequency at a second time. The method further includes a main control board that receives an indication of a user's condition, compares the first oscillator frequency with the second oscillator frequency to determine a frequency drift, calibrates the frequency drift based on the received indication of the condition of the user, and determines a blood glucose level of the user based on the calibrated frequency drift. A corresponding wearable blood glucose monitoring device and apparatus are also provided.

traducir

METHOD FOR ADJUSTING A BOLUS AMOUNT OF INSULIN, DEVICE AND MEDICAL SYSTEM

NºPublicación: EP3483891A1 15/05/2019

Solicitante:

ROCHE DIABETES CARE GMBH [DE]
HOFFMANN LA ROCHE [CH]

Resumen de: EP3483891A1

The present disclosure refers to a method for adjusting a bolus amount of insulin for a meal event using a control unit having a processing unit and a touch screen display as well as a medical control device and a medical system configured to perform the method. Additionally the present disclosure refers to a computer program or computer program product which when executed performs the method.

traducir

PREVENTION OF PROTEIN GLYCATION USING LYSINE SUPPLEMENTS

NºPublicación: US2019134084A1 09/05/2019

Solicitante:

LYSULIN INC [US]

US_2019134083_A1

Resumen de: US2019134084A1

A method of preventing protein glycation using a supplement may comprise: administering a supplement comprising lysine and zinc; monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.

traducir

PREVENTION OF PROTEIN GLYCATION USING LYSINE/ZINC SUPPLEMENTS

NºPublicación: US2019134083A1 09/05/2019

Solicitante:

BURD JOHN [US]

US_2019134084_A1

Resumen de: US2019134083A1

A method of preventing protein glycation using a supplement may comprise: administering a supplement comprising lysine and zinc; monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.

traducir

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

NºPublicación: US2019135856A1 09/05/2019

Solicitante:

UNIV VIRGINIA COMMONWEALTH [US]

US_2018127457_A1

Resumen de: US2019135856A1

5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.

traducir

PREVENTION OF PROTEIN GLYCATION USING LYSINE/ZINC SUPPLEMENTS

NºPublicación: WO2019089068A1 09/05/2019

Solicitante:

LYSULIN INC [US]
BURD JOHN [US]

US_2019134083_A1

Resumen de: WO2019089068A1

A method of preventing protein glycation using a supplement may comprise: administering a supplement comprising lysine and zinc; monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.

traducir

SYSTEMS AND METHODS FOR PROVIDING PROFESSIONAL TREATMENT GUIDANCE FOR DIABETES PATIENTS

NºPublicación: WO2019090107A1 09/05/2019

Solicitante:

TIGAR HEALTH INC [US]

US_2019131007_A1

Resumen de: WO2019090107A1

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

traducir

REMOTE ANALYTE MONITORING AND INSULIN DELIVERY SYSTEM

NºPublicación: WO2019089891A1 09/05/2019

Solicitante:

SENSEONICS INCORPORATED [US]

US_2019125969_A1

Resumen de: WO2019089891A1

In one aspect, an analyte monitoring and insulin delivery system is provided. The system may include an analyte sensor configured to convey sensor data indicative of a measurement of one or more detectable properties based on an amount or concentration of an analyte. The system may include a transceiver configured to receive the sensor data and calculate an analyte level based on the sensor data. The system may include a display device configured to receive calculate an adjusted insulin delivery rate for an insulin pump and display the received analyte level and/or the adjusted insulin delivery rate. The system may include the insulin pump configured to increase, decrease or maintain a first insulin delivery rate based on the adjusted insulin delivery rate. The display device may further display icons corresponding to the system components and an operational status indicator for each icon.

traducir

DIABETES MANAGEMENT PARTNER INTERFACE FOR WIRELESS COMMUNICATION OF ANALYTE DATA

NºPublicación: WO2019089324A1 09/05/2019

Solicitante:

DEXCOM INC [US]

US_2019125224_A1

Resumen de: WO2019089324A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.

traducir

INSULIN INJECTION DEVICE PROVIDED WITH A NEEDLE PUSH-EJECTION MECHANISM, AND NEEDLE FOR SAME

NºPublicación: WO2019085231A1 09/05/2019

Solicitante:

HUAIAN EFAST INNOVATION TECH CO LTD [CN]

CN_107693901_A

Resumen de: WO2019085231A1

An insulin injection device provided with a needle push-ejection mechanism, and needle for same, the device comprising a dose delivery mechanism (1), a cartridge holder (2) and an injection needle (3). The cartridge holder (2) is tubular and adapted to hold a cartridge (4). A viewing window (21) is provided on the cartridge holder (2) to allow axial viewing of the volume of drug in the cartridge (4). A rear end of the cartridge holder (2) is attached to the dose delivery mechanism (1). A front end of the cartridge holder (2) or the cartridge (4) is provided with a mounting boss (5) adapted to connect to the injection needle (3). The injection needle (3) comprises a shaft (31), a hub (32) and an adapter (33). The shaft (31) is mounted on the hub (32), which is attached to the adapter (33). The injection needle (3) locks onto the mounting boss (5). An ejection sleeve (6) is sheathed over or within the wall of the cartridge (2). The diameter of the aperture at a front end of the ejection sleeve (6) is greater than the diameter of the mounting boss (5) but smaller than the diameter of the adapter (33). Axial sliding of the ejection sleeve (6) is restricted by the front end of the cartridge holder (2). The present invention allows quick and convenient fitting and removal of needles, and is safe, as it is possible to remove needles without touching them, reducing the risk of accidental injury to the operator.

traducir

SYSTEMS AND METHODS FOR GRADED GLUCOSE CONTROL

NºPublicación: WO2019090016A1 09/05/2019

Solicitante:

BOSTON SCIENT SCIMED INC [US]

US_2019125226_A1

Resumen de: WO2019090016A1

A system may include a controller operably connected to a diabetic therapy delivery system. The controller may be configured to: receive therapy inputs including a therapy input indicative of a glucose measure; determine a therapy input index using the at least one therapy input including the therapy input indicative of a glucose measure; map the determined therapy input index to a graded glucose control; and set the graded glucose control based on the mapped graded glucose control for the determined therapy input index, wherein the graded glucose control includes at least one of a neuromodulation target, a neuromodulation type, or at least one neuromodulation parameter value. The diabetic therapy delivery system may be configured to deliver the therapy for graded glucose control using the graded glucose control that was set based on the mapped graded glucose control.

traducir

REGIMEN ADHERENCE MEASURE FOR INSULIN TREATMENT BASED ON GLUCOSE MEASUREMENTS AND INSULIN PEN DATA

NºPublicación: EP3479267A1 08/05/2019

Solicitante:

NOVO NORDISK AS [DK]

CN_109416945_A

Resumen de: WO2018001853A1

Systems and methods are provided for adjusting a standing insulin medicament dosage regimen for a subject. Fasting events are identified using autonomous timestamped glucose measurements of the subject in a first data set. A second data set, from one or more insulin pens used to apply the standing regimen, comprises records, each record comprising a timestamped event specifying an amount of injected insulin medicament. Each fasting event is characterized as adherent or nonadherent. A fasting event is adherent when the second data set includes one or more records that temporally and quantitatively establish adherence with the standing regimen during the fasting event. Conversely, a fasting event is nonadherent when the second data set fails to temporally and quantitatively establish adherence with the standing regimen. Dosages in the standing regimen are adjusted using glucose measurements contemporaneous with adherent fasting events and by excluding glucose measurements contemporaneous with nonadherent fasting events.

traducir

SYSTEMS AND METHODS FOR ANALYSIS OF INSULIN REGIMEN ADHERENCE DATA

NºPublicación: EP3479266A1 08/05/2019

Solicitante:

NOVO NORDISK AS [DK]

CN_109313932_A

Resumen de: WO2018001854A1

Systems and methods are provided for monitoring adherence to an insulin medicament dosage regimen for a subject. A data set comprising a plurality of metabolic events the subject engaged in within a period of time is obtained. Each respective metabolic event comprises a timestamp of the event and a characterization that is one of insulin regimen adherent and insulin regimen nonadherent. A plurality of primary adherence values is calculated, each respective adherence value representing a corresponding time window in a plurality of time windows within the period of time. Each time window is of a same first fixed duration. Each respective adherence value is computed by dividing a number of insulin regimen adherent events by a total number of events that have timestamps in the time window corresponding to the respective adherence value. The adherence values across the period of time are communicated thereby monitoring adherence to the insulin regimen.

traducir

SYSTEMS AND METHODS FOR ANALYSIS OF INSULIN REGIMEN ADHERENCE DATA

NºPublicación: EP3479263A1 08/05/2019

Solicitante:

NOVO NORDISK AS [DK]

CN_109416935_A

Resumen de: WO2018001855A1

System and methods are disclosed for monitoring adherence to a prescribed insulin regimen for a subject. A data set comprising a plurality of metabolic events the subject engaged is obtained. Each metabolic event comprises a timestamp of the event and a first classification that is one of insulin regimen adherent and nonadherent. Each respective metabolic event is then further classified using a second classification, based upon the timestamp of the metabolic event. The second classification has a temporal periodicity represented by a plurality of periodic elements. Metabolic events are binned on the basis of the second classification thereby obtaining a plurality of subsets of the metabolic events, each subset for a different periodic element. For each respective subset, a respective representation of adherence to the insulin regimen is communicated, the representation of adherence being collectively based upon the first classification of metabolic events in the respective subset.

traducir

SYSTEM FOR SUBCUTANEOUS INTRODUCTION OF MEDICINAL SOLUTIONS, COMBINED WITH PARACORPORAL DISPENSER

NºPublicación: RU2687181C1 07/05/2019

Solicitante:

OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU KONTINENTAL MED [RU]

Resumen de: RU2687181C1

FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to medical equipment, and can be used for independent subcutaneous injections in treating diabetes mellitus, various inflammatory diseases, etc. Task solved by the proposed technical solution is creation of a universal infusion system combined with paracorporal dispenser of different manufacturers, design of a system which is convenient and cost-effective to use, reliable in operation, high-tech in production. Technical result is achieved by using an infusion system for subcutaneous administration of a drug solution containing a skin-mounted infusion device connected by a connective catheter with a solution delivery port, as well as a syringe for installing an infusion set on the skin. Port of invasive system has inner thread and outer Luer cone in center, wherein system is additionally equipped with two adapters, in which on the side of system external thread is made with pitch and diameter identical to internal thread and system port pitch, and inner Luer cone, and on the side connected to the paracorporal dispenser, an external thread is made with pitch and diameter identical to the internal thread and pitch of the fitting of the corresponding dispenser, and an internal Lewer cone or needle.EFFECT: reliable and sealed connection both to the port of the infusion system and to the outlet nozzle of the paracorporal dispenser for medicinal solutions by means of a set of adapters.1 cl, 1 dwg

traducir

Insulin patch pump

Nº publicación: US10279106B1 07/05/2019

Solicitante:

TANDEM DIABETES CARE INC [US]

Resumen de: US10279106B1

A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament through tubing to an infusion site displaced from the pump.

traducir

Página1 de 5 nextPage por página

punteroimgVolver